On July 20, Insilico Medicine rose 6.71% in regular trading, trading at HK$45.9/share, with turnover of HK$203 million.

On the news front, the World Artificial Intelligence Conference is currently underway in Shanghai, where Insilico Medicine's founder and CEO was interviewed and expressed optimistic views on China's AI development prospects. Meanwhile, the Life Sciences Tools & Services sector saw a broad recovery, with Pharmaron up 6.03%, WuXi XDC up 5.91%, WuXi Biologics up 4.87%, Joinn up 4.21%, and WuXi AppTec up 3.73%.

The rally comes amid a series of recent positive developments for the company, including a strategic alliance with Bora Pharmaceuticals potentially valued over $2.5 billion, a collaboration with Takeda Pharmaceutical worth up to $600 million, and a positive profit alert projecting first-half net profit of $33.5-39.5 million on revenue of approximately $103-107 million, marking a swing from loss to profit year-over-year.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)